Key Takeaways:
- PMS and PMDD differ in severity—PMDD involves intense mood symptoms that impair daily life and require medical intervention.
- The root cause isn’t hormone levels but sensitivity—women with PMS/PMDD react abnormally to normal hormonal shifts, affecting brain chemistry.
- Lifestyle changes help, especially diet, exercise, and stress reduction—but severe cases often need SSRIs or hormonal treatments.
- PMDD is underdiagnosed but highly treatable—tracking symptoms and seeking professional care leads to significant improvement.
Menstrual Pain
For countless women, the days leading up to their period can feel like an unrelenting storm—far beyond a fleeting moment of discomfort. Physical aches, unpredictable mood swings, and overwhelming emotional lows can transform routine tasks into daunting challenges, casting a shadow over work, relationships, and personal well-being. Often dismissed as “just PMS,” these symptoms can range from mildly disruptive to utterly debilitating, particularly for those grappling with Premenstrual Dysphoric Disorder (PMDD). Yet, there is hope: both PMS and PMDD are not only treatable but manageable with the right tools and knowledge. This comprehensive guide, grounded in rigorous clinical research and expert insights, illuminates the science behind these conditions, demystifies their causes, and offers a clear, actionable roadmap to effective treatments. Whether you’re seeking relief for yourself or supporting someone else, this resource empowers you to navigate the complexities of PMS and PMDD with confidence and clarity.
PMS vs PMDD: Definitions and Impact
Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) represent two points on the same biological spectrum, both emerging during the luteal phase of the menstrual cycle—the period after ovulation and before menstruation. What separates them is not only the severity of symptoms but the systems they primarily affect and how significantly they interfere with a woman’s ability to function.
PMS is characterized by a constellation of physical and emotional symptoms, including bloating, breast tenderness, fatigue, irritability, and mood lability. These symptoms typically begin 5 to 10 days before menstruation and resolve within a few days after its onset. PMDD, by contrast, is a recognized psychiatric disorder classified in the DSM-5 under depressive disorders (APA, 2013). It presents with more pronounced psychological disturbances: marked depression, hopelessness, severe irritability or anger, anxiety, difficulty concentrating, and a sense of being emotionally overwhelmed. Physical symptoms may still be present but are secondary to the mood-related features. Diagnosis requires prospective documentation of symptoms across at least two menstrual cycles and confirmation that they interfere significantly with work, school, or social functioning (Halbreich et al., 2003).
Importantly, PMDD is not simply “bad PMS.” While both disorders are triggered by the normal hormonal shifts of the menstrual cycle, individuals with PMDD may have a heightened sensitivity to these changes. Understanding this spectrum is critical not just for accurate diagnosis, but for appropriate treatment planning. Women with PMS may benefit from lifestyle changes and nutritional support alone, while those with PMDD often require targeted psychiatric interventions such as SSRIs or hormonal therapies.
The Roots of PMS and PMDD
Understanding why some women experience debilitating premenstrual symptoms while others do not lies in unraveling the complex interaction between the endocrine system and the brain. Both PMS and PMDD are not caused by abnormal hormone levels per se—estrogen and progesterone levels in women with these conditions are typically within normal ranges. Rather, the disorders arise from an abnormal response to otherwise normal hormonal fluctuations, particularly in the post-ovulatory, or luteal, phase of the menstrual cycle (Schmidt et al., 1998).
Hormonal Sensitivity, Not Hormonal Excess
During the luteal phase, progesterone rises as the body prepares for a potential pregnancy, while estrogen declines after ovulation. In women with PMS and especially PMDD, these hormonal changes trigger abnormal responses in brain function and mood regulation. A pivotal player in this hormonal-brain interaction is allopregnanolone, a neuroactive steroid metabolite of progesterone that modulates GABA-A receptors—the same inhibitory system affected by benzodiazepines (Bäckström et al., 2014).
Under normal circumstances, allopregnanolone has calming, anti-anxiety effects. However, in women with PMDD, this neurosteroid may cause agitation, dysphoria, and irritability, contributing to mood instability (Bäckström et al., 2014).
Serotonergic Dysregulation: The Mood Link
In parallel, estrogen and progesterone modulate key neurotransmitters—particularly serotonin, which governs mood, sleep, and appetite. Fluctuations in hormone levels can disrupt serotonin synthesis, reuptake, and receptor sensitivity. Women with PMS/PMDD may show altered serotonin activity during the luteal phase (Rubinow et al., 1998).
This explains why Selective Serotonin Reuptake Inhibitors (SSRIs)—typically used for depression—are so effective in PMS and PMDD. Unlike in major depressive disorder, SSRIs often alleviate premenstrual symptoms within days, not weeks, further suggesting that the underlying pathology is rooted in an acute neurotransmitter-hormone interaction rather than a chronic mood disorder (Halbreich et al., 2003).
A Unique Neuroendocrine Profile
What makes PMDD distinct is not only the intensity of symptoms, but the specific neurobiological response to cyclical hormonal changes. These findings support the idea that PMDD is not a psychological reaction to menstruation, but a true, cyclical neuroendocrine disorder.
By recognizing this neurobiological foundation, researchers and clinicians have shifted treatment goals from simple hormone “correction” to targeting the brain’s abnormal response to hormonal cues—explaining the central role of SSRIs and, in refractory cases, hormone-suppressing therapies like GnRH agonists.
How Symptoms Manifest in Everyday Life
The true burden of PMS and PMDD lies not merely in the presence of symptoms, but in how those symptoms reverberate through a woman’s daily functioning—physically, emotionally, and socially. While bloating, fatigue, breast tenderness, and headaches are some of the more visible physical complaints, they rarely occur in isolation. It is often the less visible emotional disturbances—irritability, sadness, anxiety, emotional lability—that are most disruptive, especially when compounded by a lack of external validation or awareness.
For many women with PMS, these symptoms feel like an unwelcome but manageable monthly disruption. They may experience a day or two of increased sensitivity or lowered energy, but they are still able to perform daily tasks, interact with others, and maintain routines. However, even in milder cases, PMS can erode patience, reduce productivity, and strain relationships—particularly in work or caregiving roles that offer little flexibility.
In contrast, PMDD exerts a much more destabilizing influence. The emotional volatility can be extreme and, crucially, cyclical—meaning the same symptoms recur predictably each month, often catching sufferers in a cycle of dread, frustration, and psychological exhaustion. A woman with PMDD might feel fine for two or three weeks, only to find herself plunged into a week of uncontrollable mood swings, crying spells, overwhelming anxiety, or rage that feels disproportionate and inexplicable. Some report intrusive thoughts of worthlessness or even suicidal ideation during this window, only to feel confusion or guilt once the episode passes (Halbreich et al., 2003).
Functionally, this can derail personal and professional life. At work, women with PMDD often describe difficulties concentrating, increased interpersonal conflict, or the need to take unscheduled leave. At home, relationships with partners, children, or roommates may become tense as irritability or emotional withdrawal disrupts communication. Social engagements are often avoided or canceled due to mood or body image concerns, reinforcing a sense of isolation. Repeated exposure to these cycles can foster anticipatory anxiety, depression, and in some cases, misdiagnosis with bipolar or major depressive disorders if the cyclic pattern is missed.
Studies show that up to 15% of women with PMDD experience suicidal ideation at some point, a rate comparable to or even exceeding some chronic mood disorders (Pearlstein et al., 2005). Importantly, this intense distress resolves spontaneously after menstruation begins, further illustrating the direct link between hormonal cycling and symptom expression.
Over time, untreated PMS or PMDD can lead to a form of learned helplessness—a resignation to suffering that delays medical care and undermines self-worth. Yet with proper recognition and treatment, the prognosis is favorable. Women often report dramatic improvements in functioning, mood, and quality of life once appropriate interventions (from SSRIs to hormonal therapy to CBT) are initiated.
Foundational Lifestyle Strategies: The First Line of Defense
For women navigating the cyclic turbulence of PMS and PMDD, lifestyle interventions offer more than just marginal relief—they lay the groundwork for long-term hormonal and emotional stability. While medications play a critical role in moderate to severe cases, a growing body of evidence affirms that changes in diet, physical activity, and stress regulation can meaningfully reduce symptom intensity and frequency, particularly for those with mild to moderate presentations.
Dietary modulation is often underestimated in managing PMS, yet the connection between micronutrients and hormonal sensitivity is well-documented. Diets rich in calcium and magnesium—found in leafy greens, dairy, legumes, and nuts—have been shown to reduce premenstrual symptoms such as irritability, fatigue, and bloating. Randomized trials suggest that women who consume 1,200 mg of calcium daily experience up to a 50% reduction in overall symptom severity within three menstrual cycles (Thys-Jacobs et al., 1998). Magnesium, meanwhile, plays a role in neurotransmitter regulation and muscle relaxation, supporting both emotional and physical stability. Reducing intake of caffeine, salt, and refined sugar is equally important, as these compounds can exacerbate mood swings, fluid retention, and blood sugar instability—all of which amplify PMS symptoms.
Exercise functions as a natural antidepressant, anti-inflammatory, and analgesic—precisely the kind of intervention needed for hormone-related mood and body symptoms. Engaging in moderate aerobic activity for 20 to 30 minutes, three to five times per week, can reduce cramps, stabilize mood, and enhance sleep. The mechanism lies in exercise-induced increases in endorphins and serotonin, which counteract the mood-destabilizing effects of luteal-phase hormonal fluctuations. Additionally, physical movement improves lymphatic drainage and reduces fluid retention, easing the sensation of bloating and heaviness that many women describe as debilitating.
Sleep and stress regulation complete the triad of foundational care. Premenstrual hormonal shifts already stress the hypothalamic-pituitary-adrenal (HPA) axis, and chronic sleep deprivation or psychological stress further dysregulates this system, leading to heightened irritability, anxiety, and emotional reactivity. Mindfulness-based stress reduction (MBSR), cognitive-behavioral therapy (CBT), and consistent sleep hygiene practices—such as maintaining regular sleep-wake times and minimizing screen use before bed—have shown measurable benefits in reducing symptom recurrence and improving overall resilience (Lustyk et al., 2009). These techniques are particularly vital for women who experience PMDD, where mood instability may be both triggered and worsened by chronic psychological or physiological stress.
While lifestyle strategies may not fully resolve symptoms in women with PMDD or severe PMS, they are often the first, safest, and most empowering tools in the therapeutic arsenal. For some, these changes alone offer substantial relief; for others, they provide a stable foundation upon which medical interventions can act more effectively. In either case, they are not merely complementary—they are essential.
When Lifestyle Isn’t Enough: Medical Options
While foundational lifestyle strategies are essential for building hormonal resilience, they may not provide sufficient relief for women with moderate to severe PMS or PMDD. In these cases, targeted pharmacological therapy offers a higher level of symptom control, grounded in neurobiological mechanisms and supported by robust clinical evidence.
SSRIs: The Gold Standard for PMDD
Among all available treatments, Selective Serotonin Reuptake Inhibitors (SSRIs)—such as fluoxetine, sertraline, and escitalopram—stand out as the most effective first-line therapy for PMDD and severe PMS. Unlike in major depressive disorder, SSRIs for PMDD often act rapidly, improving symptoms within a few days of administration. This accelerated response is likely due to their modulation of serotonin and allopregnanolone pathways, both of which are destabilized during the luteal phase in sensitive women (Pearlstein et al., 2005).
These medications can be prescribed in two ways: daily dosing (most effective for persistent symptoms) or luteal-phase dosing (beginning 14 days before menstruation). Importantly, SSRIs are not only effective for mood-related symptoms such as irritability, anger, and depression but also for physical symptoms like fatigue and breast tenderness—underscoring the interconnected neuroendocrine origin of PMDD.
Hormonal Contraceptives: Cycle Suppression
In women whose symptoms are driven by ovulatory hormonal cycling, combined oral contraceptives (COCs) offer an effective alternative. These contraceptives work by suppressing ovulation and blunting the hormonal fluctuations that trigger emotional and physical symptoms. Continuous or extended-cycle dosing (where active pills are taken for longer than 21 days without a hormone-free interval) may enhance effectiveness by maintaining stable hormonal levels.
However, these therapies may not be suitable for all patients—particularly those with contraindications to estrogen, a history of thromboembolic events, or women who experience mood destabilization on hormonal contraceptives.
NSAIDs: Targeted Relief for Physical Symptoms
For those whose primary complaints are physical—such as cramps, headaches, or breast tenderness—Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen and naproxen offer reliable, short-term relief. These medications inhibit prostaglandin synthesis, which plays a key role in uterine contractions and inflammatory responses. NSAIDs are best taken at the onset of symptoms or anticipated menstruation and are often used adjunctively with other therapies.
Supplements and Herbal Options: Adjuncts, Not Replacements
In the growing landscape of integrative medicine, certain nutritional supplements and herbal therapies have emerged as viable options for mild to moderate symptoms or as adjuncts to pharmacologic care. However, it’s critical to evaluate these agents based on rigorous scientific evidence and not anecdotal claims.
Chasteberry (Vitex agnus-castus)
Derived from the fruit of the chaste tree, Vitex has been used for centuries to address menstrual irregularities. Research has shown that Vitex may reduce a variety of PMS symptoms—including irritability, mood swings, and breast tenderness (Cerqueira et al., 2017). Its proposed mechanism involves dopamine receptor agonism, leading to suppressed prolactin levels and hormonal modulation.
However, while Vitex may reduce physical and mild emotional symptoms, it is not a substitute for SSRIs in women with dominant mood disorders. Dosages of 20–40 mg/day are generally used over at least three menstrual cycles for therapeutic benefit.
Calcium and Magnesium
Calcium carbonate, at a dose of 1,200 mg daily, has been shown in double-blind studies to reduce symptoms such as fatigue, appetite changes, and depression by up to 48% within three cycles (Thys-Jacobs et al., 1998). Magnesium, often used at 200–400 mg/day, supports neurotransmitter synthesis and has been linked to reductions in bloating, headaches, and insomnia.
These minerals are not only inexpensive and accessible, but they also carry low side-effect profiles, making them suitable as part of first-tier or maintenance therapy—especially in patients hesitant to start medication.
Recognizing When to Seek Professional Help
While occasional mood fluctuations or physical discomfort before menstruation can be a normal part of the menstrual cycle, there is a clear threshold where premenstrual symptoms move from being manageable to medically significant. That line is crossed when symptoms consistently interfere with emotional well-being, professional productivity, interpersonal relationships, or daily decision-making. Unfortunately, many women wait years before seeking help—believing their suffering is simply something to be endured. The truth is far different: PMS and PMDD are medical conditions with recognized diagnostic criteria and evidence-based treatments.
The most immediate sign that a medical evaluation is warranted is the presence of cyclical emotional symptoms that recur in the luteal phase of the cycle and remit shortly after menstruation begins. These can include mood swings, sadness, rage, anxiety, or a sense of emotional instability that is severe enough to cause distress or functional impairment. According to the DSM-5, a diagnosis of PMDD requires at least five such symptoms, one of which must be mood-related, along with documentation that they interfere with work, school, or relationships (APA, 2013).
Additionally, if lifestyle adjustments—such as improved diet, regular exercise, or sleep optimization—have been consistently attempted without sufficient relief, it’s time to escalate care. Over-the-counter remedies like NSAIDs or magnesium may blunt physical discomfort, but they are often inadequate for emotional volatility or cognitive symptoms such as difficulty concentrating, irritability, or self-critical rumination.
More alarmingly, some women with PMDD report suicidal thoughts or intense emotional despair during the premenstrual period. This level of distress should never be normalized or dismissed. Studies indicate that suicidal ideation is reported in up to 15% of women with PMDD (Pearlstein et al., 2005), making it one of the more serious mood-related disorders in gynecologic psychiatry. In such cases, immediate consultation with a mental health provider or gynecologist is not only recommended—it is essential.
A qualified clinician can guide diagnosis using tools such as the Daily Record of Severity of Problems (DRSP), which tracks symptom patterns across at least two menstrual cycles. This data-driven approach helps distinguish PMDD from chronic mood disorders like major depression or bipolar disorder, which do not show cyclical relief.
Once diagnosed, treatment options include SSRIs, which can be used either daily or only during the luteal phase; hormonal contraceptives, which suppress ovulation; and in some cases, cognitive-behavioral therapy (CBT) to help reframe catastrophic thinking patterns. For individuals with refractory symptoms, more aggressive options such as GnRH agonists—which induce temporary medical menopause—may be considered, sometimes as a bridge to surgical intervention like oophorectomy in severe cases.
In short, reaching out for professional help is not an overreaction—it is a recognition that your symptoms are real, medically significant, and, most importantly, treatable.
Related Reading:
Depression: A Gene May Explain Why Women Are Most Affected
Swimming in Cold Water Shown to Have a Positive Impact on Menstrual and Perimenopausal Symptoms
FAQs
What is the difference between PMS and PMDD?
PMS causes moderate symptoms; PMDD includes severe mood issues that disrupt life.
What causes PMS and PMDD?
Hormonal shifts after ovulation trigger brain changes, especially in serotonin and GABA systems.
Are these conditions due to hormonal imbalance?
No, hormone levels are typically normal—it’s the brain’s sensitivity that’s abnormal.
How common are PMS and PMDD?
PMS affects up to 40% of menstruating women; PMDD affects about 3% to 8%.
When do symptoms typically occur?
During the luteal phase—after ovulation and before menstruation.
Can symptoms start later in life?
Yes, onset can happen anytime during reproductive years, especially after childbirth or in the 30s.
Is PMDD a psychiatric disorder?
Yes, it’s listed under depressive disorders in the DSM-5.
Can PMS/PMDD mimic depression or anxiety?
Yes, but the symptoms are cyclical, which distinguishes them from chronic mood disorders.
How is PMDD diagnosed?
By tracking symptoms for at least two cycles and identifying a luteal-phase pattern.
Can these conditions cause suicidal thoughts?
Yes, particularly in PMDD, which has a high rate of emotional distress.
Are PMS and PMDD treatable?
Yes—effective options include SSRIs, hormonal therapies, CBT, and lifestyle changes.
Do SSRIs really work for PMDD?
Yes, they often work within days and target serotonin dysregulation during the luteal phase.
Can hormonal birth control help?
Yes, especially those containing drospirenone, which can suppress hormone fluctuations.
What are some natural remedies that help?
Calcium, magnesium, Vitex (chasteberry), and regular exercise have shown benefits.
Do dietary changes make a difference?
Yes—reducing sugar, caffeine, and salt while increasing calcium and magnesium helps many women.
How does exercise help PMS/PMDD?
It boosts serotonin, reduces cramps, and improves sleep and mood.
Is cognitive behavioral therapy effective?
Yes, CBT can reduce mood symptoms and improve emotional coping strategies.
Do PMS/PMDD affect relationships?
Often—mood swings, irritability, and withdrawal can strain personal connections.
Should I tell my partner or employer about PMDD?
Yes, open communication can lead to better support and understanding.
Can PMS/PMDD impact work performance?
Yes, concentration, energy, and emotional regulation can be impaired during symptom days.
Can I predict which days symptoms will be worst?
Yes, tracking cycles can reveal a consistent pattern.
What is a “luteal-phase treatment plan”?
A proactive routine to manage symptoms in the two weeks before menstruation.
Can birth control make PMDD worse?
Yes, in some women; it’s important to monitor symptoms when starting or changing pills.
What if nothing helps my PMDD?
Options include GnRH agonists or surgery, but only for severe, unresponsive cases.
Can PMDD go away on its own?
It may lessen after menopause, but active treatment is usually needed before then.
Is PMS/PMDD linked to other conditions?
Yes, it can overlap with depression, anxiety, or thyroid disorders.
Can sleep help reduce symptoms?
Definitely—good sleep stabilizes mood and hormone responses.
Is stress a major trigger?
Yes, stress worsens both emotional and physical symptoms.
Can PMS or PMDD be misdiagnosed?
Frequently—often mistaken for bipolar disorder or generalized anxiety.
How do I advocate for better care?
Track your symptoms, bring data to appointments, and push for evidence-based treatments.
Final Thoughts
Premenstrual disorders like PMS and PMDD are not simply private struggles—they are public health issues that deserve the same scientific rigor, empathy, and innovation we apply to other chronic conditions. Yet for generations, these conditions have been minimized, mischaracterized, or misunderstood. The lived experience of millions of women tells a different story: this is a condition that can hijack cognition, sabotage relationships, and erode self-esteem. But it is also a condition that can be managed—when we treat it as seriously as the data demands.
If you’re struggling with recurring premenstrual symptoms, here are five actionable insights to carry forward:
- Track With Precision
Begin a two-month log of your physical, emotional, and cognitive symptoms. Use validated tools like the Daily Record of Severity of Problems (DRSP). Tracking not only validates your experience—it turns anecdote into clinical evidence. - Think Beyond Hormones
PMS and PMDD are not “hormone problems” in the traditional sense. They are neuroendocrine disorders. This reframing is crucial. Treatment should target serotonin systems (via SSRIs), GABA modulation (via neurosteroid research), and thought patterns (via CBT). - Design a Personalized “Luteal Plan”
Once you’ve identified your symptomatic days, create a monthly “self-care contract” for that phase. Prioritize flexible scheduling, reduce high-stakes meetings, front-load demanding tasks earlier in the cycle, and have strategies in place—whether medication, therapy check-ins, or calming routines—to proactively manage symptoms. - Build a Social Contract With Those Around You
Partners, family, friends, and even employers can become allies—not skeptics—when they are informed. Consider sharing your diagnosis, cycle calendar, or treatment goals with key people in your life. The burden shouldn’t be yours alone to carry. - Demand Better Medicine and More Research
PMDD is one of the few psychiatric conditions that can be reliably predicted down to the day—and yet it remains under-researched. Ask your provider about clinical trials, new neurosteroid treatments in development, or innovative non-pharmaceutical options like open-label placebos or cycle-based CBT. Your curiosity fuels clinical progress.
Finally, remind yourself: hormonal sensitivity is not a weakness. It is a form of biological diversity—one that requires specialized care, not stigmatization. The goal isn’t to “tough it out” or silence symptoms with brute willpower. The goal is to reclaim predictability, agency, and joy in your life. And with the right tools and support, that goal is absolutely within reach.
References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
Bäckström, T., Haage, D., Löfgren, M., Johansson, I. M., Strömberg, J., Nyberg, S., Andréen, L., Ossewaarde, L., van Wingen, G. A., Turkmen, S., & Bengtsson, S. K. (2011). Paradoxical effects of GABA-A modulators may explain sex steroid-induced negative mood symptoms in some persons. Neuroscience, 191, 46–54. https://doi.org/10.1016/j.neuroscience.2011.03.061
Bäckström, T., Bixo, M., Johansson, M., Nyberg, S., Ossewaarde, L., Ragagnin, G., Savic, I., Strömberg, J., Timby, E., van Broekhoven, F., & van Wingen, G. (2014). Allopregnanolone and mood disorders. Progress in Neurobiology, 113, 88–94. https://doi.org/10.1016/j.pneurobio.2013.07.005
Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology, 28(Suppl 3), 1–23. https://doi.org/10.1016/S0306-4530(03)00098-2
Cerqueira, R. O., Frey, B. N., Leclerc, E., & Brietzke, E. (2017). Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: A systematic review. Archives of Women’s Mental Health, 20(6), 713–719. https://doi.org/10.1007/s00737-017-0791-0
Lustyk, M. K., Gerrish, W. G., Shaver, S., & Keys, S. L. (2009). Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: A systematic review. Archives of Women’s Mental Health, 12(2), 85–96. https://doi.org/10.1007/s00737-009-0052-y
Pearlstein, T., Yonkers, K. A., Fayyad, R., & Gillespie, J. A. (2005). Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of Affective Disorders, 85(3), 275–282. https://doi.org/10.1016/j.jad.2004.10.004
Rubinow, D. R., Schmidt, P. J., & Roca, C. A. (1998). Estrogen–serotonin interactions: Implications for affective regulation. Biological Psychiatry, 44(9), 839–850. https://doi.org/10.1016/S0006-3223(98)00162-0
Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine, 338(4), 209–216. https://doi.org/10.1056/NEJM199801223380401
Thys-Jacobs, S., Starkey, P., Bernstein, D., & Tian, J. (1998). Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. American Journal of Obstetrics and Gynecology, 179(2), 444–452. https://doi.org/10.1016/S0002-9378(98)70377-1
